Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories.

Adolescent Eosinophil count Eosinophilic inflammation Interleukin-5 Mepolizumab Severe asthma

Journal

Asia Pacific allergy
ISSN: 2233-8276
Titre abrégé: Asia Pac Allergy
Pays: Netherlands
ID NLM: 101561954

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 17 12 2019
accepted: 02 04 2020
entrez: 16 5 2020
pubmed: 16 5 2020
medline: 16 5 2020
Statut: epublish

Résumé

Real-world experience with mepolizumab for pediatric asthma is still limited. We report 3 patients who were treated with mepolizumab for severe adolescent asthma. Two patients, a 12-year-old boy and a 14-year-old girl, responded well to mepolizumab and showed apparent improvement in lung function from a downward trend over time before treatment. The third patient, a 16-year-old boy, whose treatment was switched from omalizumab to mepolizumab, did not have satisfactory response. The 2 successful cases had eosinophil counts of 440 and 371/μL and multiple comorbid allergic diseases including food allergies. The clinical benefit to them included elimination of both exacerbation and exercise-induced asthma. Interestingly, the boy's food-induced gastrointestinal symptoms disappeared following start of mepolizumab treatment.

Identifiants

pubmed: 32411578
doi: 10.5415/apallergy.2020.10.e13
pmc: PMC7203436
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e13

Informations de copyright

Copyright © 2020. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.

Déclaration de conflit d'intérêts

Conflict of Interest: The authors have no financial conflicts of interest.

Références

J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2689-2696.e2
pubmed: 31201938
Lancet Respir Med. 2018 Jul;6(7):535-544
pubmed: 29628376
N Engl J Med. 2016 May 12;374(19):1842-1852
pubmed: 27168434
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1385-1395
pubmed: 28862877
Clin Rev Allergy Immunol. 2018 Aug;55(1):88-98
pubmed: 29234969
Eur Respir J. 2013 Nov;42(5):1224-33
pubmed: 23520319
Immunol Allergy Clin North Am. 2018 May;38(2):165-182
pubmed: 29631728
Gastroenterology. 2011 Nov;141(5):1593-604
pubmed: 21835135
Respir Med Case Rep. 2019 Jul 09;28:100899
pubmed: 31341763
Pediatrics. 2001 Aug;108(2):E36
pubmed: 11483846
N Engl J Med. 2011 Mar 17;364(11):1005-15
pubmed: 21410369
J Allergy Clin Immunol. 2017 Apr;139(4):1167-1175.e2
pubmed: 27726946
J Allergy Clin Immunol. 2007 Apr;119(4):817-25
pubmed: 17353040
Prim Care Respir J. 2009 Mar;18(1):41-9
pubmed: 19240948
Allergol Int. 2015 Oct;64(4):364-70
pubmed: 26433533
Eur Respir J. 2015 Sep;46(3):856-9
pubmed: 26022964
Lancet Respir Med. 2017 May;5(5):362-363
pubmed: 28395935
Chest. 2008 Feb;133(2):404-11
pubmed: 18071011
Allergy Asthma Clin Immunol. 2019 Sep 3;15:53
pubmed: 31507641

Auteurs

Miyuki Hoshi (M)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Mayumi Matsunaga (M)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Kazutaka Nogami (K)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Kana Hamada (K)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Taiga Kobori (T)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Keigo Kainuma (K)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Mizuho Nagao (M)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Takao Fujisawa (T)

Department of Clinical Research, National Hospital Organization Mie National Hospital, Tsu, Japan.

Classifications MeSH